UCLA Startup, ImaginAb, Closes $21 Million Series B Financing

UCLA brainchild ImaginAb has hauled in another $21 million in venture cash to advance its antibody-re-engineering technology

From FierceBiotech:

“UCLA brainchild ImaginAb has hauled in another $21 million in venture cash to advance its antibody-re-engineering technology, a biotech approach to imaging that the company believes will help personalize treatments for cancer and immune disease.

Mérieux Développement, the investment arm of French life sciences outfit bioMérieux, led the latest round, joined by repeat investors Novartis ($NVS), Cycad Group and Nextech Invest. Each is betting ImaginAb’s novel take on imaging agents will help investigators better understand disease and match patients to their ideal therapies…”

READ FULL ARTICLE [web]
Read Press Release [web]
About ImaginAb [web]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s